<DOC>
	<DOCNO>NCT01095926</DOCNO>
	<brief_summary>Analyze pharmacokinetics doxorubicin child cancer . Furthermore investigate predictive role troponin natriuretic peptide anthracycline-induced cardiotoxicity .</brief_summary>
	<brief_title>Pharmacokinetic Study Doxorubicin Children With Cancer</brief_title>
	<detailed_description>- Paediatric patient age 17 year include . Number time point PK sample depend age tumour type . - PK sample collect two doxorubicin administration . Analyzing sample two doxorubicin administration allow distinguish interindividual , intraindividual residual variability . - Doxorubicin major metabolite doxorubicinol measure plasma use HPLC - In addition , natriuretic peptide BNP precursor NT-pro ANP NT-proBNP well troponin T measure plasma 28 day doxorubicin administration evaluate use clinical marker cardiotoxicity . - A data set max 5 sample ( 3 +2 ( 1st + 2nd Doxorubicin sample period ) ) collect young child ( &lt; 3 year ) data set max . 8 sample ( 5 + 3 ) collect old child . Samples take predefined time points/ time interval . - An additional DNA sample take analyzed genetic polymorphism . The influence genotype pharmacokinetics metabolism investigate appropriate statistical method , include population pharmacokinetic analysis . Genes study would include MDR1 SLC22A16 , involve transport doxorubicin AKR1A1 CBR1 , involve reduction doxorubicin doxorubicinol . Selected genotype incorporate covariates population pharmacokinetic model develop . The potential impact genetic variation evaluate context source variability age , weight , gender etc</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>patient ≤ 17 year age plan receive least two cycle doxorubicin must enrol national European protocol treatment Wilms Tumours , Neuroblastoma , Soft tissue sarcoma , Ewing Sarcoma Acute lymphoblastic leukaemia must treat doxorubicin accord protocol Or Patients &lt; 3 year enrol listed national European study protocol paediatric malignancy . Treatment doxorubicin accord protocol . Parents legal representative ( ) must provide write informed consent participate trial accord national regulation . Patients able understand provide assent participate trial . Life expectancy least 3 month Karnofsky performance status ≥ 70 % Additional blood withdrawal acceptable patient . The decision leave investigator prior cardiac problem</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>cancer</keyword>
	<keyword>troponin</keyword>
	<keyword>natriuretic peptide</keyword>
	<keyword>cardiotoxicity</keyword>
	<keyword>anthracyclines</keyword>
	<keyword>Ewing</keyword>
	<keyword>ALL</keyword>
</DOC>